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Lecithin:cholesterol acyltransferaseHyperhomocysteinemia results from hepatic metabolism dysfunction and is characterized by a high plasma ho-
mocysteine level, which is also an independent risk factor for cardiovascular disease. Elevated levels of homocys-
teine in plasma lead to hepatic lesions and abnormal lipid metabolism. Therefore, lowering homocysteine levels
might offer therapeutic benefits. Recently, wewere able to lower plasma homocysteine levels inmicewithmod-
erate hyperhomocysteinemia using an adenoviral construct designed to restrict the expression of DYRK1A, a
serine/threonine kinase involved in methionine metabolism (and therefore homocysteine production), to hepa-
tocytes. Here, we aimed to extend our previous findings by analyzing the effect of hepatocyte-specific Dyrk1a
gene transfer on intermediate hyperhomocysteinemia and its associated hepatic toxicity and liver dysfunction.
Commensuratewith decreased plasma homocysteine and alanine aminotransferase levels, targeted hepatic expres-
sion of DYRK1A in mice with intermediate hyperhomocysteinemia resulted in elevated plasma paraoxonase-1 and
lecithin:cholesterol acyltransferase activities and apolipoprotein A–I levels. It also rescued hepatic apolipoprotein E,
J, and D levels. Further, Akt/GSK3/cyclin D1 signaling pathways in the liver of treatedmice were altered, whichmay
help prevent homocysteine-induced cell cycle dysfunction.DYRK1A gene therapy could be useful in the treatment of
hyperhomocysteinemia in populations, such as end-stage renal disease patients, who are unresponsive to
B-complex vitamin therapy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystathionine beta synthase (CBS) deficiency is the most common
inborn error of one-carbon metabolism and is the cause of classical
homocystinuria, a condition characterized by high levels of plasma ho-
mocysteine (hcy) or severe hyperhomocysteinemia (hhcy) [1]. Elevatedolipoprotein; CBS, cystathionine
cy, homocysteine; HDLs, high-
igh-performance liquid chroma-
cyltransferase; NQO1, NAD(P)H:
olymerase chain reaction; PBS,
SAH, S-adenosylhomocysteine;
density lipoprotein.
é Paris Diderot — Paris 7, Case
is cedex 13, France.
. This is an open access article underplasma hcy, or hhcy, is categorized by range asmoderate (15 to 30 μM),
intermediate (30 to 100 μM), and severe (above 100 μM). Hyperhomo-
cysteinemia is associated with increased risk for congenital disorders,
including neural tube closure defects, heart defects, cleft lip/palate,
Down syndrome, and multi-system abnormalities in adults [2].
hcy is a thiol-containing amino acid produced during metabolism
of methionine (an essential amino acid supplied by dietary proteins)
via the adenosylated compounds S-adenosylmethionine (SAM) and S-
adenosylhomocysteine (SAH). The metabolism of hcy occurs at the junc-
tion of two pathways: remethylation, the process leading to the recon-
struction of the methionine particle, and the transsulfuration pathway.
Conversion of hcy to cystathionine is catalyzed by CBS, which is vitamin
B6-dependent and functions first in the transsulfuration pathway. hcy
can also revert to SAH via reversal of the S-adenosylhomocysteine hydro-
lase (SAHH) reaction [3]. Increased hcy synthesis and its slower intracel-
lular utilization cause increased efflux into the blood. Hence, plasma hcy
level is an important reflection of hepatic methionine metabolism andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ferent enzymes [4].
Current treatment for CBS deficiency involves lowering hcy levels
with a combination of vitamins, protein restriction, and cysteine supple-
mentation [5–7]. Although treatments can be effective, the challenging
dietary regimens often create problems with compliance. However,
approximately 50% of patientswith CBS deficiency are biochemically re-
sponsive to pyridoxine (vitamin B6) and show improvement in plasma
hcy levels [8]. Therefore, drugs that could stimulate residual CBS en-
zyme activity could be useful in treating the disease.
One possible approach to stimulating CBS activity is by using gene
therapy to deliver a gene (and, therefore, protein) that could increase
the activity of existing CBS protein in the liver. We recently used an
adenoviral construct designed to restrict overexpression of DYRK1A, a
serine/threonine kinase involved in several steps of methionine metab-
olism, to hepatocytes of hhcy mouse models [9,12]. Indeed, we have
demonstrated the involvement of hepatic Dyrk1a levels on hepatic
SAHH and CBS activities by a mechanism dependent of NAD(P)H:
quinone oxidoreductase (NQO1) activity and pyridoxal phosphate
respectively [10–12]. Injection of the specific adenoviral Dyrk1a gene
transfer construct to mice with moderate hhcy produced decreased
plasma hcy levels, in agreement with restoration of key enzymes of hcy
metabolism, SAHHandCBS. Pyridoxal phosphate, themetabolically active
form of vitamin B6 and cofactor of CBS, was elevated, consistent with the
increase in CBS activity [11].
As the central organ of metabolism, many metabolic diseases origi-
nate in the liver; however, clinical manifestations can be extrahepatic.
In the case of hhcy, the liver plays not only a central role in the metab-
olism of methionine and contributes the high levels of plasma hcy, but
also produces and degrades lipoproteins. High-density lipoproteins
(HDLs) exert potent protective effects, including the prevention and
correction of endothelial dysfunction by their anti-oxidative and their
anti-inflammatory properties [13]. Commensuratewith decreased plas-
ma hcy levels, targeted hepatic expression ofDyrk1a by adenoviral gene
transfer resulted in elevated activity of plasma paraoxonase-1 (PON-1),
an HDL-associated protein that inactivates lipids in oxidized low-
density lipoproteins, and increased plasma levels of apolipoprotein A–I
(APO A–I), the major protein component of HDLs. Additionally, the
Akt/GSK3 signaling pathways were rescued in the aorta of targeted
mice, thus preventing hcy-induced endothelial dysfunction [11]. In the
current study, we aimed to extend our previous findings by analyzing
the effect of hepatocyte-specific Dyrk1a gene transfer on intermediate
hhcy and on the associated hepatic toxicity by measuring plasma ala-
nine aminotransferase (ALT) levels, and liver dysfunction bymeasuring
lipid markers.
2. Materials and methods
2.1. Experimental animals
All procedureswere carried out in accordancewith internal guidelines
of the French Agriculture Ministry for animal handling. Mice were main-
tained in a controlled environment with unlimited access to food and
water on a 12 h light/dark cycle. Mice were fed a standard laboratory
diet (CRM, Special Diets Services, Dietex, France Usine). This diet has
a protein content of 19%, a methionine content of 2.700 mg kg−1, a
folic acid content of 4.41 mg kg−1, and a vitamin B12 content of
0.082 mg kg−1. The number of mice and suffering were minimized as
possible. Mice heterozygous for targeted disruption of the Cbs gene
(Cbs+/−) were generously donated by Dr. N. Maeda (Department of Pa-
thology, University of North Carolina, Chapel Hill, NC, USA) [12]. Cbs+/−
mice, on a C57BL/6 background, were obtained by mating male Cbs+/−
mice with female wild-type C57BL/6 (Cbs+/+) mice. DNA isolated
from tail biopsies of 4-week-old mice was subjected to genotyping of
the targeted Cbs allele using polymerase chain reaction (PCR) [14]. The
E1E3E4-deleted adenoviral vector “AdDYRK1A” was constructed toinduce hepatocyte specific overexpression of DYRK1A as described
previously [11]. Generation of the E1E3E4-deleted adenoviral vector
“AdDYRK1A” and large-scale vector production were performed as
described previously [15]. Before the experiments and to induce inter-
mediate hhcy, female Cbs+/−mice, 3 at 4months of age,weremaintained
for three months on the standard diet supplemented with 0.5%
L-methionine (Sigma-Aldrich, France) in drinkingwater.Micewere divid-
ed into two groups for the last month, with one group receiving injection
in the retro-orbital sinus with an adenoviral vector AdDYRK1A to have
2 × 1012 adenoviral particles/kg body weight and the second group re-
ceiving an equivalent dose of saline buffer [11]. Controlmice, healthy con-
trol Cbs+/+ mice also received an equivalent dose of saline buffer and
wereused as references tomonitor hyperhomocysteinemic development.
Five to twelve mice per experiment were used.
2.2. Preparation of serum samples, tissue collection, and plasma assays
Upon euthanization of mice by Ketamine/Xylazine intraperitoneal
injection, blood samples were obtained by retro-orbital sinus sampling
with heparinized capillaries, collected into tubes containing a 1/10
volume of 3.8% sodium citrate, and immediately placed on ice. Plasma
was isolated by centrifugation at 2500 ×g for 15 min at 4 °C. Livers
were harvested, snap-frozen, and stored at −80 °C until use. Plasma
total hcy, defined as the total concentration of hcy after quantitative
reductive cleavage of all disulfide bonds, was assayed using the fluori-
metric high-performance liquid chromatography (HPLC) method as
previously described [16]. Samples were treated with perchloric acid
and kynurenic acid (KYNA) was quantified by LC-MS/MS with CTC-
PAL autosampler on an Agilent 1200 series system with a quaternary
pump, and MS detection was performed on an API 3200 MS/MS spec-
trometer (ABSciex) operated with a Turbo Ion Spray source [17].
KYNA used as standard was purchased from Sigma-Aldrich. Data were
acquired and processed using Analyst software (V. 1.4.2). Plasma APO
A–I protein levelsweremeasured byELISA (E90519M,Uscn, Life Science
Inc.) according to the manufacturer's instructions. After the develop-
ment of the colorimetric reaction, optical density (OD) at 450 nm was
quantified by a microplate reader (Flex Station3, Molecular Device),
and OD readings were converted to concentrations (μg/mL) on the
basis of the standard curve obtainedwithAPOA–I standard preparation.
ALT was assayed using the Alanine Aminotransferase Activity Assay Kit
(Sigma-Aldrich, France), based on the pyruvate generated.
2.3. Protein extraction and slot blot analysis
Liver protein extracts were prepared by homogenizing tissue in
phosphate-buffered saline (PBS) with a cocktail of protease inhibitors
(1 mM Pefabloc SC, 5 μg/mL E64, and 2.5 μg/mL Leupeptin). Homoge-
nates were centrifuged at 12,500 ×g for 15 min at 4 °C. Supernatants
were then assayed for protein concentrations with the Coomassie
(Bradford) Protein Assay reagent (Bio-Rad). Since specificity of each pri-
mary antibody used was previously validated byWestern blotting, pro-
tein extracts (40 μg) under reducing conditions were subjected to slot
blotting on nitrocellulose transfer membrane PROTRAN® (Whatman).
The membrane was then blocked in 10% nonfat dry milk in Tris–saline
buffer (1.5 mM Tris, 5 mMNaCl, 0.1% Tween-20) and probed overnight
at 4 °C with one of the following antibodies: anti-APO D (1/1000; Santa
Cruz Biotechnology, Tebu, France), anti-APO E (1/1000; Santa Cruz
Biotechnology), anti-APO J (1/1000; Santa Cruz Biotechnology), anti-
DYRK1A (1/250; Abnova Corporation, Tebu, France), anti-Akt (1/1000;
Santa Cruz Biotechnology), anti-phospho-Akt1/2/3 (Ser 473; 1/1000;
Santa Cruz Biotechnology), anti-GSK (1/2000, Santa Cruz Biotech-
nology,), anti-phospho-GSK3 (ser21-9; 1/400, Cell Signaling,
Ozyme, France), or anti-cyclin D1 (1/250, Cell Signaling). Horserad-
ish peroxidase-conjugated secondary antibody and Western Blotting
Luminol Reagent (Santa Cruz Biotechnology) were used to detect specific
proteins. Digitized images of the immunoblots obtained using an LAS-
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metric measurements with an image analyzer (UnScan It software, Silk
Scientific Inc.). Quantification of total proteins after Ponceau-S coloration
was used as an internal control.Fig. 1. Effect of hepatic overexpression of Dyrk1a on plasma hcy levels and hepatic CBS activity
(b), and CBS activity in the liver (c) of wild-type (Cbs+/+)mice and Cbs+/−mice supplemented
AdDYRK1A. DYRK1A level was determined by slot blotting, and values were obtained by norma
expression andCBS activitywere normalized to themean ofwild-typemice (Cbs+/+). Data corr
and hepatic CBS activity were negatively correlated at p b 0.0013 with a ρ=−0.861 for hcy le
related at p b 0.01 with a ρ= 0,655 (e).2.4. Enzyme activity assays
CBS activity assaywas performed on 300 μg of protein extracts as de-
scribed previously [18]. Proteins were incubated for 1 h at 37 °C within mice with intermediate hhcy. DYRK1A protein expression in the liver (a), hcy in plasma
withmethionine and injected (Cbs+/−Met/AdDYRK1A) or uninjected (Cbs+/−Met) with
lization of images from DYRK1A to total proteins colored with Ponceau-S. Data of DYRK1A
espond to themedianswith interquartile ranges. n=number ofmice. Levels of plasmahcy
vels N5 μM (d). Levels of hepatic Dyrk1a expression and CBS activity were positively cor-
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L-serine, 10 mM DL-hcy, and 0.8 mM S-(5′-adenosyl)-L-methionine,
using a DTNB [5,5′-dithiobis-(2-nitrobenzoic acid)] based-assay.
The reaction was performed at 37 °C by measuring the absorbance
at 412 nm over 10 min, using a spectrophotometer (Lambda XLS,
PerkinElmer). Lecithin:cholesterol acyltransferase (LCAT) activity
was assayed on 2 μL of plasma with an LCAT kit per manufacturer's
directions (Calbiochem/EMD-Millipore/Merck KGaA, Darmstadt,
Germany). NAD(P)H:quinone oxidoreductase (NQO1) activity was
assayed on 150 μg of protein extracts as described [19]. Proteins were in-
cubated for 8 min at room temperature in PBS containing 0.07% bovine
serum albumin (pH 7.4) and 0.01% Tween-20. Then, amixture containing
0.2mMβ-nicotinamide adenine dinucleotide, reduced (NADH), 5 μM fla-
vin adenine dinucleotide (FAD), and 25mMTris–HCl (pH 7.4)was added
to the protein preparations. Two conditions were prepared, with or with-
out 10 μmol of dicoumarol (Calbiochem, MERCK) used to specifically
block NQO1. The reaction was started by adding 40 μM of 2,6-
dichlorophenolindophenol (DCPIP). The reduction of DCPIP was assayed
bymeasuring the absorbance at 600 nmevery 30 s for 3min using a spec-
trophotometer (Lambda XLS, PerkinElmer). NQO1 activity was deter-
mined by subtraction of the activity recorded in the presence of
dicoumarol. PON1 activity assaywas performed on 100 μg of liver protein
extracts or 5 μL of plasma. PON1 arylesterase activity toward phenyl ace-
tate was quantified spectrophotometrically using 20 mM Tris–HCl
(pH 8.3), 1 mM CaCl2, and 10 mM phenyl acetate. The reaction was per-
formed at room temperature by measuring the appearance of phenol at
270 nm every 10 s for 1 min using a spectrophotometer (Lambda XLS,
PerkinElmer). SAHH activity was measured in the forward hydrolysis di-
rection following the protocol described by Villanueva and Halsted [20]Fig. 2. Effect of hepatic overexpression of Dyrk1a on plasma ALT and KYNA levels inmice with in
mice supplementedwithmethionine and injected (Cbs+/−Met/AdDYRK1A) or uninjected (Cbs
number of mice. Levels of plasma ALT and hcy were positively correlated at p b 0.011 with a ρ=
ρ= 0.563 (d).with some modifications. Protein extracts (300 μg) were incubated for
5 min at 37 °C in 1 mL of reaction mixture (452 mM NaCl, 8.9 mM KCl,
33mMNa2HPO4, 6.6mMKH2PO4, 0.1% gelatin, 1.2mMMTT, 1.1U aden-
osine deaminase, 0.45 U nucleoside phosphorylase, and 0.1 U xanthine
oxidase). The SAHH reaction was started by adding 80 μM S-(5′-
adenosyl)-L-homocysteine to the mixture. Following 5 min of incubation
at 37 °C, SAHH-specific activity was detected by the production of
formazan, which is detected by measuring the absorbance at 578 nm
using a spectrophotometer (Lambda XLS, PerkinElmer).
2.5. Data analysis
Statistical analysis was done with one-way ANOVA followed by
Fisher post-hoc test using Statview software. The results are expressed
as medians with interquartile ranges. Data were considered significant
when p ≤ 0.05. A p value of 0.06–0.10 was considered to indicate a
strong statistical tendency due to the small sample size. Correlations
were determined by using Spearman's rank correlation, as data were
not normally distributed according to Shapiro–Wilk test.
3. Results
3.1. Dyrk1a overexpression reduces plasma hcy levels in mice with
intermediate hhcy
To overexpress Dyrk1a specifically in the liver of mice, we used an
E1E3E4-deleted adenoviral vector “AdDYRK1A”, whichwas constructed
to induce hepatocyte-specific expression of Dyrk1a [11]. We injected
“AdDYRK1A” into CBS-deficient mice (Cbs+/−) supplemented withtermediate hhcy. ALT (a) and KYNA (b) in plasma ofwild-type (Cbs+/+)mice and Cbs+/−
+/−Met) with AdDYRK1A. Data correspond to themedianswith interquartile ranges. n=
0.543 (c). Levels of plasma ALT and KYNAwere negatively correlated at p b 0.024 with a
55A. Latour et al. / Molecular Genetics and Metabolism Reports 2 (2015) 51–60methionine in drinking water, a murine intermediate model of hhcy.
Similar to a previous report [9], mean DYRK1A protein level was
decreased in the liver of Cbs+/− mice supplemented with methio-
nine when compared with wild-type (Cbs+/+) mice (Fig. 1a). How-
ever, after injection of AdDYRK1A to Cbs+/− mice supplemented
with methionine, we observed an increase in DYRK1A protein levels
when compared with Cbs+/− mice supplemented with methionine
but uninjected (Fig. 1a).
To determine the effect of DYRK1A overexpression on plasma hcy
levels in intermediate hhcy, we quantified plasma levels of hcy in
Cbs+/− mice supplemented with methionine with or without Dyrk1a
gene transfer. As expected, the hcy level in Cbs+/−mice supplemented
withmethioninewas higher than that of Cbs+/+mice (Fig. 1b). Interest-
ingly, Cbs+/− mice supplemented with methionine and injected with
AdDYRK1A had a significantly lower plasma hcy level than uninjected
Cbs+/−mice (Fig. 1b).
We next studied hepatic activities of the main enzymes implicated
in hcy metabolism. Assays of hepatic CBS activity revealed, as expected,
significantly lower activity in Cbs+/−mice supplemented with methio-
nine than in Cbs+/+ mice (Fig. 1c). Injection of AdDYRK1A resulted in a
significant increase in CBS activity (Fig. 1c). A Spearman correlation test
revealed a significant negative correlation between plasma hcy levels
and hepatic CBS activity for hcy levels N5 μM (ρ = −0.861, p b
0.0013, Fig. 1d), and a significant positive correlation between liver
Dyrk1a expression and CBS activity (ρ = 0.655, p b 0.01, Fig. 1e).
Since hcy is lowered by its conversion into SAH, we also assayed
SAHH activity in the liver of mice and found an increase after injection
of AdDYRK1A (100.2 ± 9.7 versus 146.1 ± 18.1; p b 0.05; n = 8 forFig. 3. Effect of hepatic overexpression of Dyrk1a on PON1 and LCAT activity in mice with int
wild-type (Cbs+/+) mice and Cbs+/−mice supplemented with methionine and injected (Cbs+
to the mean of wild-type mice (Cbs+/+). Data correspond to the medians with interquartile ra
correlated at p b 0.05 with a ρ=−0.423 (d).each). We previously reported that increased SAHH activity occurs
concomitantly with an increase in NQO1 activity [10,11]. Therefore,
we assayed hepatic NQO1 activity to confirm this finding in the
intermediate hhcy model. After injection of AdDYRK1A, we ob-
served a significant increase in NQO1 activity (100.3 ± 6.6 versus
136.6 ± 9.7; p b 0.01; n = 8 for each).
3.2. Dyrk1a overexpression reduces plasma ALT and increases kynurenic
acid levels in mice with intermediate hhcy
Hepatocellular injury often results in an increase in serum ALT, and
serum ALT levels are used as a marker for liver injury. To determine
the effect of Dyrk1a overexpression on liver damage, we quantified
plasma levels of ALT in Cbs+/− mice supplemented with methionine
with or without Dyrk1a gene transfer. The mean ALT level in Cbs+/−
mice supplemented with methionine was significantly higher than
that of Cbs+/+mice (Fig. 2a). In contrast, in Cbs+/−mice supplemented
with methionine and injected with AdDYRK1A, ALT level was signifi-
cantly lower than in uninjected Cbs+/−mice (Fig. 2a).
Previous results have shown that low concentrations of hcy stimu-
late production of the tryptophan derivative KYNA, whereas high levels
inhibit KYNA formation in vitro and in vivo [21]. Interestingly, KYNA
might exert a protective role on multiple organs during heatstroke
through anti-inflammatory mechanisms [22]. Here, we found that
the plasma levels of KYNA were significantly lower in Cbs+/− mice
supplemented with methionine but trended higher after injection
with AdDYRK1A (Fig. 2b). Moreover, a Spearman correlation test re-
vealed a significant positive correlation between plasma ALT andermediate hhcy. Hepatic PON1 activity (a) and plasma PON1 (b) and LCAT (c) activity in
/−Met/AdDYRK1A) or uninjected (Cbs+/−Met) with AdDYRK1A. Data were normalized
nges. n = number of mice. Levels of plasma LCAT activity and hcy levels were negatively
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KYNA levels (Fig. 2d) (ρ= 0.543, p b 0.01; ρ=−0.563, p b 0.05, re-
spectively). These results confirm the deleterious effect of hhcy on
liver and support a beneficial effect of DYRK1A expression on rescu-
ing the hhcy phenotype.Fig. 4. Effect of hepatic overexpression ofDyrk1a on apolipoprotein levels inmicewith intermed
(f) levels in wild-type (Cbs+/+) mice and Cbs+/−mice supplemented with methionine and inje
D, APO J, andAPOE expressionswere normalized to themean ofwild-typemice (Cbs+/+). Data
and hepatic APO D levels were positively correlated at p b 0.02 with a ρ= 0.567 (d).3.3. DYRK1A overexpression rescues enzymes involved in HDL metabolism
in mice with intermediate hhcy
PON-1 is an HDL-associated protein that plays a major role in HDL-
mediated protection against coronary artery disease [23], and hepaticiate hhcy. PlasmaAPOA–I (a), APOD (b) levels and hepatic APOD (c), APO J (e), and APO E
cted (Cbs+/−Met/AdDYRK1A) or uninjected (Cbs+/−Met) with AdDYRK1A. Hepatic APO
correspond to themedianswith interquartile ranges. n=number ofmice. Levels of plasma
Fig. 5. Effect of hepatic overexpression of Dyrk1a on IkB levels in mice with intermediate
hhcy. IkB protein expression in the liver ofwild-type (Cbs+/+)mice and Cbs+/−mice sup-
plementedwithmethionine and injected (Cbs+/−Met/AdDYRK1A) or uninjected (Cbs+/−
Met) with AdDYRK1A. IkB expression was determined by slot blotting, and values were
obtained by normalization of images from IkB to total proteins colored with Ponceau-S.
Data of IkB expression were normalized to the mean of wild-type mice (Cbs+/+). Data
correspond to the medians with interquartile ranges. n = number of mice.
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ity was therefore investigated in the context of hhcy and Dyrk1a gene
transfer rescue models. As expected, Cbs +/−mice supplemented with
methionine exhibited lower hepatic PON1 activity than Cbs+/+ mice
(Fig. 3a). After injection of AdDYRK1A, we observed a significant in-
crease in hepatic PON1 activity (Fig. 3a). Since PON1 is synthesized in
the liver and is secreted into the serum, the activity of PON1was also ex-
amined in plasma. Cbs+/− mice supplemented with methionine had
significantly lower plasma PON1 activity than Cbs+/+ mice (Fig. 3b).
Injection of AdDYRK1A resulted in significantly higher plasma
PON1 activity (Fig. 3b). A Spearman correlation test revealed a sig-
nificant negative correlation between plasma PON1 activity and
plasma hcy as well as ALT levels (ρ=−0.631, p b 0.01; ρ=−0.576,
p b 0.05 respectively).
LCAT enzyme converts cholesterol into long-chain cholesteryl esters
on HDLs and promotes cholesterol transport from tissues into HDLs.
Thus, LCAT is a key enzyme in cholesterol homeostasis and transport
regulation [25]. To further investigate the cholesterol-related effects of
the Dyrk1a gene transfer in hhcy mice, we analyzed the LCAT activity.
Cbs+/− mice supplemented with methionine had significantly lower
plasma LCAT activity than Cbs+/+mice (Fig. 3c). Injection of AdDYRK1A
resulted in significantly higher plasma LCAT activity (Fig. 3c). A Spear-
man correlation test revealed a significant negative correlation between
plasma LCAT activity and plasma hcy levels (ρ = −0.423, p b 0.05)
(Fig. 3d).
3.4. Dyrk1A overexpression rescues apolipoprotein levels in mice with
intermediate hhcy
Because Cbs+/− mice injected with AdDYRK1A displayed higher
plasma LCAT activity, we analyzed plasma APO A–I levels and hepatic
expression of apolipoproteins D (APO D) and J (APO J). Each of these
apolipoproteins is a component of HDL. APOA-I, themajor protein com-
ponent of HDL, is a co-factor of LCAT. ApoDmay stabilize LCAT [26]. APO
J, or Clusterin, associateswith HDL as one of its twomain functions [27].
We previously found that plasma APO A–I levels are correlated with
plasma hcy level and is increased in moderate hhcy mice injected with
AdDYRK1A [10]. As in mice with moderate hhcy, mice with intermedi-
ate hhcy exhibited significantly lower circulating levels of APO A–I com-
pared to Cbs+/+mice (Fig. 4a). Further, AdDYRK1A injection resulted in
a significant increase in plasma APO A–I levels (Fig. 4a). A Spearman
correlation test revealed a significant negative correlation between
plasma APO A–I and hcy levels (ρ = −0.569, p b 0.02). Consistent
with the results for plasma APO A-I, Cbs+/− mice supplemented with
methionine also exhibited significantly lower plasmaAPOD andhepatic
levels of APO D and APO J compared to Cbs+/+mice (Fig. 4b, c, e), while
AdDYRK1A injection resulted in a significant increase (Fig. 4b, c, e). A
Spearman correlation test revealed a significant positive correlation be-
tween plasma and hepatic levels (ρ= 0.567, p b 0.02) (Fig. 4d).
APO E, on the other hand, is a polymorphic and pleiotropic apolipo-
protein mainly synthesized by the liver and is a component of very low-
density lipoprotein (VLDL) and HDL [28]. VLDLs are major contributors
to atherosclerosis. Cbs+/−mice supplementedwithmethionine exhibited
significantly higher hepatic levels of APO E compared to Cbs+/+ mice
(Fig. 4f). AdDYRK1A injection resulted in a significant decrease in hepatic
APO E levels (Fig. 4f).
3.5. Dyrk1a overexpression rescues hepatic IkB levels in mice with
intermediate hhcy
The secondmajor function of APO J is to negativelymodulate theNF-
kB signaling pathway by stabilizing its inhibitor, IkB [27]. We therefore
analyzed IkB protein expression in the liver of mice and, commensurate
with the decreased levels of APO J, Cbs+/−mice supplementedwithme-
thionine exhibited significantly lower hepatic levels of IkB compared toCbs+/+ mice (Fig. 5). Moreover, AdDYRK1A injection resulted in a
significant increase in IkB levels (Fig. 5).
3.6. Dyrk1a overexpression rescues hepatic Akt/GSK3 signaling pathways in
mice with intermediate hhcy
Given the link between DYRK1A and the PI3K/Akt pathway [29,30],
we analyzed the activation of Akt in the liver of mice. Commensurate
with the decreased DYRK1A protein levels in the liver of Cbs+/− mice
supplemented with methionine, phospho-Akt levels were decreased
(Fig. 6a). This decreased activation was rescued following injection of
AdDYRK1A to Cbs+/−mice supplemented with methionine (Fig. 6a).
Akt phosphorylates GSK3 alpha and beta on inhibitory serine
residues 21 and 9, respectively. No significant difference was found for
GSK3 or phosphorylated GSK3 levels between Cbs+/+ mice and
Cbs+/−mice supplemented with methionine (Fig. 6b, c). However, sig-
nificantly lower GSK3 (Fig. 6b) and higher phosphorylated GSK3
(Fig. 6c) levels were found in the liver of Cbs+/− mice supplemented
with methionine after injection of AdDYRK1A.
GSK3 phosphorylates cyclin D1 to trigger its degradation. Cyclin D1
levelswere similar betweenCbs+/+mice andCbs+/−mice supplemented
with methionine (Fig. 6d). However, injection of AdDYRK1A induced a
significant increase in cyclin D1 level in Cbs+/− mice supplemented
with methionine (Fig. 6d).
3.7. Dyrk1a overexpression rescues brain DYRK1A expression in mice with
intermediate hhcy
Many studies reported the link between DYRK1A overexpression
and cognitive impairment [29]. Moreover, we also found an increase
in DYRK1A protein expression in brain of hhcy mice [31,32]. Similar to
our previous reports [31,32], mean DYRK1A protein level was increased
in brain of Cbs+/−mice supplemented with methionine when compared
with wild-type (Cbs+/+) mice (Fig. 7). However, after injection of
AdDYRK1A to Cbs+/−mice supplementedwithmethionine, we observed
a decrease in DYRK1A protein levels when compared with Cbs+/−mice
supplemented with methionine but uninjected (Fig. 7).
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We recently demonstrated decreased plasma hcy levels inmicewith
moderate hhcy after adenovirus-mediated Dyrk1a gene transfer to
hepatocytes [11]. Here, we confirmed this positive effect of DYRK1A ex-
pression on plasma hcy levels in mice with intermediate hhcy. Not only
the negative correlation between plasma hcy levels and hepatic CBS ac-
tivity but also the positive correlation between liver Dyrk1a expression
and CBS activity underline the role of Dyrk1a in one carbonmetabolism
[9,11,12]. Further, the positive correlation identified here between plas-
ma hcy and ALT levels emphasizes the deleterious effect of hhcy on liver
function and the beneficial effect of DYRK1Aonhepatic hcymetabolism.
Although hcy is produced in the liver, hhcy is a risk factor for cardio-
vascular diseases [33], and lowering hcy levels could offer a viable ap-
proach to preventing cardiovascular diseases. Our findings demonstrate
the link betweenhepatic and vascular functions.We found anegative cor-
relation between ALT and KYNA levels. hcy lowered KYNA production in
cultured bovine aortic endothelial cells [34]. Interestingly, KYNA exerts a
protective effect against hcy-induced impairment of endothelial cells
in vitro [35]. Vascular endothelial cells can also be impaired by lipopro-
teins, and changes in lipid metabolism and lipoproteins are often ob-
served in cardiovascular diseases. Importantly, a correlation between
serum hcy levels and lipids and lipoproteins has been observed [36]. A
high concentration of LDL is found in patients with hhcy and primaryFig. 6. Effect of hepatic overexpression of Dyrk1a on phospho-Akt, GSK3, phospho-GSK3, and cycli
expression (b), phosphorylation of GSK3 alpha and beta on ser 21 and 9 (c), and cyclin D1 expres
onine and injected (Cbs+/−Met/AdDYRK1A) or uninjected (Cbs+/−Met) with AdDYRK1A. GSK
normalization of images from GSK3 and cyclin D1 to total proteins colored with Ponceau-S. Relat
total Akt or GSK3. Data were normalized to the mean of wild-type mice (Cbs+/+). Data corresponhypertension, coupled to enhanced secretion of VLDL triglycerides [37].
VLDLs and LDLs are considered as one of the most important pro-
atherogenic factors, and APO E is a major component of these particles.
We found an increased hepatic APO E level in mice with intermediate
hhcy, which was abolished after injection of AdDYRK1A. In the vascula-
ture, VLDL and LDL particles are susceptible to oxidative modifications.
The COMAC group studies have confirmed the existence of several pro-
atherogenic factors, such as the disruption of lipids and lipoprotein bal-
ance, for which hhcy intensifies their negative effects on cardiovascular
function [38]. Increased hepatic APO E level can also be explained as a
compensatory protective effect. Indeed, APO E has a high affinity to LDL
receptors on hepatic and extrahepatic cells. In mice, APO E deficiency
causes accumulation in plasma of cholesterol-rich VLDL remnants for
whichprolonged circulation is atherogenic [39]. Conversely, the increased
synthesis of hepatic APO E could increase the synthesis of APO E-rich
VLDL, and those remnants could be cleared more rapidly due to their
increased affinity for LDL receptor.
We found decreased hepatic APO D and plasma APO A–I levels in
mice with intermediate hhcy, which was abolished after injection of
AdDYRK1A. APO D and APO A–I are components of HDL particles. The
observed decreases in APOD andAPOA–Imay be responsible for the re-
duced plasma LCAT activity also observed in mice with intermediate
hhcy. Moreover, the decreased LCAT activity was abolished after injec-
tion of AdDYRK1A. Indeed, APO A–I is a cofactor of LCAT activity, andn D1 levels in mice with intermediate hhcy. Phosphorylation of Akt (a), GSK3 alpha and beta
sion (d) in the liver of wild-type (Cbs+/+)mice and Cbs+/−mice supplemented withmethi-
3 and cyclin D1 expression were determined by slot blotting, and values were obtained by
ive protein expression was determined by normalization from p-Akt or p-GSK3 with that of
d to the medians with interquartile ranges. n = number of mice.
Fig. 7.Effect of hepatic overexpression ofDyrk1aonbrainDYRK1Aprotein expression inmice
with intermediate hhcy. DYRK1Aprotein expression in brain ofwild-type (Cbs+/+)mice and
Cbs+/− mice supplemented with methionine and injected (Cbs+/− Met/AdDYRK1A) or
uninjected (Cbs+/− Met) with AdDYRK1A. DYRK1A expression was determined by slot
blotting, and valueswere obtainedbynormalization of images fromDYRK1A to total proteins
colored with Ponceau-S. Data of DYRK1A expression were normalized to the mean of
wild-type mice (Cbs+/+). Data correspond to the medians with interquartile ranges. n =
number of mice.
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long-chain cholesteryl esters onHDL and promote cholesterol transport
from tissues into HDL [25], and thus are key enzymes in cholesterol ho-
meostasis and transport regulation. We found a negative correlation
between plasma hcy levels and plasma LCAT activity, and between plas-
ma hcy and APO A–I levels. Mice with intermediate hhcy also had de-
creased PON1 activity, which was abolished after injection of
AdDYRK1A. PON1 is an HDL-associated enzyme that prevents LDL oxi-
dation [23]. We found a negative correlation between plasma PON1 ac-
tivity and not only hcy but also ALT levels. Taken together, these results
emphasize the deleterious effect of hhcy on the synthesis and the mat-
uration of HDLs, and injection of AdDYRK1A can correct the deleterious
effects linked to hhcy.
Similarly, APO J levels were lower in mice with intermediate hhcy,
but this change was abolished after injection of AdDYRK1A. APO J has
two functions, one in associating with HDL, and the other (Clusterin)
in negatively modulating NF-kB signaling by stabilizing its inhibitor,
IkB [27]. Commensurate with the decreased levels of APO J, mice with
intermediate hhcy exhibited significantly lower hepatic levels of IkB,
and injection of AdDYRK1A rescued this effect. Therefore, the decreased
APO J levels found in the liver of mice with intermediate hhcy could be
responsible for hepatic inflammation [41,42], and AdDYRK1A could play
an anti-inflammatory role.
We previously showed aortic PI3K/Akt inhibition and GSK3 activa-
tion in mice with moderate hhcy [11]. Targeted hepatic expression of
AdDYRK1A resulted in lower plasma hcy, and subsequent PI3K/Akt acti-
vation and GSK3 inhibition in the aorta of mice, which can prevent en-
dothelial dysfunction [11]. Another study showed that hhcy inhibits
hepatic proliferation during liver regeneration and phosphorylation of
Akt [43,44]. Since the PI3K/Akt signaling pathway,which is downstream
of growth factor receptors, is important in promoting cell survival and
proliferation [45], we analyzed the effect of intermediate hhcy and
found a decrease in Akt phosphorylation in the liver of mice. Targeted
hepatic expression through injection of AdDYRK1A resulted in PI3K/
Akt activation and GSK3 inhibition in the liver of mice, consistent with
findings in moderate hhcy mice delivered AdDYRK1A. There are twomain stages during liver regeneration: activation of quiescent hepato-
cytes, which is controlled by cytokines such as TNF-α and IL-6, and pro-
gression in the G1 phase of the cell cycle, which is controlled by growth
factors and cyclin D1. Cyclin D1 regulates the cell cycle G1/S transition.
We found a non-significant decrease in cyclin D1 in the liver of mice
with intermediate hhcy, and injection of AdDYRK1A produced in-
creased cyclin D1. Thus, hepatic dysfunction may be explained by cell
cycle arrest and impaired liver regeneration in mice with intermediate
hhcy. Akt can enhance expression of cyclin D1 through enhancing its
translation and inhibiting protein degradation [46]. Thus, the increase
in cyclin D1 in the presence of AdDYRK1A is probably due to the in-
creased phosphorylation of Akt.
We previously showed that targeted hepatic expression of
AdDYRK1A abolished the decreased aortic DYRK1A protein level in
hhcy mice [11]. Here we found that targeted hepatic expression of
AdDYRK1A abolished the increased DYRK1A level in the brain of hhcy
mice, whichmay be the result of hcy lowering. DYRK1A hasmultiple bi-
ological functions, and its overexpression can deregulate many genes in
embryonic brains ofmice [47]. DYRK1A inhibition is also considered as a
target in neurodegeneration [48]. Considering the role of DYRK1A in
cognitive functions and hhcy as a risk factor for neurodegenerative dis-
eases [49], our results emphasize the fact that the liver constitutes the
best appropriate target for DYRK1A gene transfer in case of hhcy.
5. Conclusion
Injection of AdDYRK1A can ameliorate intermediate hhcy and its as-
sociated hepatic dysfunction. Thus, DYRK1A gene therapy could be use-
ful in the treatment of hhcy in populations, such as end-stage renal
disease patients, which are resistant to hcy lowering by B-complex vita-
min therapy. Although we found an increased SAHH activity after
AdDYRK1A injection, we do not determine if this increase can modify
the methylation status, which needs to be explored.
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